Provided by Tiger Trade Technology Pte. Ltd.

Jasper Therapeutics

0.6603
-0.0404-5.77%
Post-market: 0.6601-0.0002-0.03%19:30 EDT
Volume:294.29K
Turnover:202.51K
Market Cap:21.97M
PE:-0.71
High:0.7110
Open:0.6933
Low:0.6600
Close:0.7007
52wk High:2.69
52wk Low:0.3151
Shares:33.27M
Float Shares:30.00M
Volume Ratio:1.17
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9300
EPS(LYR):-3.9545
ROE:-255.05%
ROA:-113.41%
PB:15.55
PE(LYR):-0.17

Loading ...

Jasper Therapeutics to Join H.C. Wainwright Global Investment Conference Fireside Chat

Reuters
·
Sep 09

Jasper Therapeutics Announces Special Shareholder Meeting

Reuters
·
Sep 05

Jasper Therapeutics Announces Special Shareholder Meeting

Reuters
·
Aug 25

Analysts Offer Insights on Healthcare Companies: Aptevo Therapeutics (APVO) and Jasper Therapeutics (JSPR)

TIPRANKS
·
Aug 18

Jasper Therapeutics initiated with an Overweight at Piper Sandler

TIPRANKS
·
Aug 17

Novo, LightPath, Jasper, UMAC, CCEP Trending With Analysts

TIPRANKS
·
Aug 15

Jasper Therapeutics Q2 EPS $(0.10) Beats $(0.26) Estimate

Benzinga Earnings
·
Aug 15

Jasper Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Jasper Therapeutics Q2 Loss Per Share Beats Estimates, Raises $132 Mln

Reuters
·
Aug 14

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 14

Jasper Therapeutics Q2 Net Income USD -2.8 Million

THOMSON REUTERS
·
Aug 14

Biren Amin Initiates Buy on Jasper Therapeutics, Highlighting KP-104’s Differentiated Dual-Pathway Mechanism and $1.5B Peak Sales Potential in Kidney Diseases

TIPRANKS
·
Aug 12

Jasper Therapeutics Initiated at Overweight by Piper Sandler

Dow Jones
·
Aug 12

Jasper Therapeutics, Inc. : Piper Sandler Initiates Coverage with Overweight Rating; Target Price $2

THOMSON REUTERS
·
Aug 12

Jasper Therapeutics, Inc. Expected to Post a Loss of 35 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know

TIPRANKS
·
Aug 07

JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst

TIPRANKS
·
Aug 07

Jasper Therapeutics Shareholders Back Board, Auditors, Pay Plan

TIPRANKS
·
Aug 04

Jasper Therapeutics Holds Annual Stockholders Meeting; 75% of Shares Represented

Reuters
·
Aug 04

Jasper Therapeutics COO Matthew E. Ros Files Initial Beneficial Ownership Statement

Reuters
·
Jul 23